MA32223B1 - Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation - Google Patents

Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation

Info

Publication number
MA32223B1
MA32223B1 MA33240A MA33240A MA32223B1 MA 32223 B1 MA32223 B1 MA 32223B1 MA 33240 A MA33240 A MA 33240A MA 33240 A MA33240 A MA 33240A MA 32223 B1 MA32223 B1 MA 32223B1
Authority
MA
Morocco
Prior art keywords
her2
methods
combinations
agents
chemotherapy drugs
Prior art date
Application number
MA33240A
Other languages
Arabic (ar)
English (en)
Inventor
Leanne Berry
Gail Lewis Phillips
Mark X Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40858064&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA32223B1 publication Critical patent/MA32223B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

L'invention concerne des combinaisons du conjugué anticorps-médicament trastuzumab-mcc-dm1 et d'agents chimiothérapiques, y compris des stéréoisomères, des isomères géométriques, des tautomères, des solvates, des métabolites et des sels de qualité pharmaceutique de ceux-ci, qui s'utilisent pour inhiber la croissance de cellules de tumeur, et pour traiter des troubles tels qu'un cancer à médiation par her2 et kdr (récepteur 1 de vegfr). Des procédés d'utilisation de telles combinaisons pour un diagnostic, une prévention ou un traitement in vitro, in situ et in vivo de tels troubles dans des cellules de mammifère, ou d'affections pathologiques associées, sont divulgués.
MA33240A 2008-03-18 2010-10-11 Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation MA32223B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3741008P 2008-03-18 2008-03-18
PCT/US2009/036608 WO2009117277A2 (fr) 2008-03-18 2009-03-10 Combinaisons de conjugués anticorps anti-her2-médicament et d’agents chimiothérapiques, et procédés d’utilisation

Publications (1)

Publication Number Publication Date
MA32223B1 true MA32223B1 (fr) 2011-04-01

Family

ID=40858064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33240A MA32223B1 (fr) 2008-03-18 2010-10-11 Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation

Country Status (29)

Country Link
US (5) US8663643B2 (fr)
EP (6) EP2254571B1 (fr)
JP (5) JP5656823B2 (fr)
KR (8) KR20160125535A (fr)
CN (5) CN104873980B (fr)
AR (1) AR070865A1 (fr)
AU (1) AU2009225877B2 (fr)
BR (1) BRPI0906181A2 (fr)
CA (3) CA3146422A1 (fr)
CL (1) CL2009000559A1 (fr)
CR (2) CR20180483A (fr)
DK (3) DK2644194T3 (fr)
ES (4) ES2629405T3 (fr)
HK (1) HK1147444A1 (fr)
HU (3) HUE035184T2 (fr)
IL (7) IL295098A (fr)
MA (1) MA32223B1 (fr)
MX (3) MX2010010168A (fr)
MY (4) MY184496A (fr)
NZ (4) NZ587706A (fr)
PH (4) PH12014502134A1 (fr)
PL (4) PL2254571T3 (fr)
RU (2) RU2510272C2 (fr)
SG (3) SG10202104314YA (fr)
SI (3) SI2644204T1 (fr)
TW (4) TWI574698B (fr)
UA (2) UA127472C2 (fr)
WO (1) WO2009117277A2 (fr)
ZA (1) ZA201006186B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006216732C1 (en) * 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2008109440A2 (fr) 2007-03-02 2008-09-12 Genentech, Inc. Elément de prévision de la réponse à un inhibiteur de her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2570731T3 (es) 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
ES2502940T3 (es) 2008-08-05 2014-10-06 Toray Industries, Inc. Composición farmacéutica para el tratamiento y la prevención del cáncer
BRPI1006189A2 (pt) * 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
TW201129380A (en) * 2009-12-04 2011-09-01 Genentech Inc Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
KR20120111739A (ko) 2009-12-31 2012-10-10 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) 키나제 억제제로서의 사용을 위한 삼환식 화합물
EP2532743B1 (fr) 2010-02-04 2015-04-15 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prévention du cancer
WO2012062694A1 (fr) * 2010-11-08 2012-05-18 Novartis Ag Utilisation de dérivés 2-carboxamide cycloamino urée dans le traitement de maladies dépendantes d'egfr ou de maladies qui ont acquis une résistance aux agents qui ciblent des membres de la famille d'egfr
EP2648719A1 (fr) * 2010-12-09 2013-10-16 F.Hoffmann-La Roche Ag Traitement de cancer her2-positif avec du paclitaxel et du trastuzumab-mcc-dm1
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012278944B2 (en) * 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
EP3321281B1 (fr) 2011-08-05 2019-11-27 biOasis Technologies Inc Fragments de p97 avec activité de transfert
JP6062442B2 (ja) 2011-10-13 2017-01-18 ジェネンテック， インコーポレイテッド 薬剤誘発性低酸症の治療
DK2766040T3 (da) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
CA2864864C (fr) 2012-02-21 2020-05-12 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prevention du cancer
AU2013223147B2 (en) 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
IN2014KN01715A (fr) 2012-02-21 2015-10-23 Toray Industries
BR112014021099A2 (pt) 2012-02-21 2020-12-01 Toray Industries, Inc anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo
EP4252855A3 (fr) * 2012-03-23 2023-11-15 Array Biopharma, Inc. Composés pour utilisation dans le traitement de métastases cérébrales chez un patient atteint de cancer du sein erbb2+
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2718348T3 (es) 2012-07-19 2019-07-01 Toray Industries Método para detectar cáncer
PT2876447T (pt) 2012-07-19 2020-02-03 Toray Industries Método para deteção de cancro
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
WO2014055634A1 (fr) * 2012-10-02 2014-04-10 Yale University Identification de petites molécules inhibitrices d'histone déméthylase à de domaine jumonji 1a (jarid1a) et 1b (jarid1b) interactif riche en at,
MX363188B (es) * 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
WO2014138186A1 (fr) * 2013-03-05 2014-09-12 The Johns Hopkins University Systèmes d'administration bi-composant bioorthogonal pour l'internalisation améliorée de produits nanothérapeutiques
WO2014160438A1 (fr) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments de p97 et leurs utilisations
EP2968591A1 (fr) * 2013-03-15 2016-01-20 Novartis AG Inhibiteurs de la prolifération cellulaire et leurs conjugués
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA2921412A1 (fr) * 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des diastereomeres macrolides, leurs procedes de synthese et leurs utilisations therapeutiques
BR112016011430B1 (pt) 2013-11-19 2022-09-13 Purdue Research Foundation Compostos, conjugado de anticorpo, composição farmacêutica os compreendendo e seus usos
KR101854443B1 (ko) * 2013-11-19 2018-06-15 레메젠 리미티드 항-her2 항체 및 이의 접합체
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
EP3973995A1 (fr) * 2014-01-31 2022-03-30 Daiichi Sankyo Company, Limited Conjugué anticorps-médicament anti-her2
AU2015210612B2 (en) 2014-02-03 2020-04-09 Bioasis Technologies Inc. P97 fusion proteins
JP6605482B2 (ja) 2014-02-19 2019-11-13 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７−ｉｄｓ融合タンパク質
US9737535B2 (en) * 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
EP3134440A1 (fr) 2014-04-25 2017-03-01 F. Hoffmann-La Roche AG Méthodes de traitement du cancer du sein précoce avec du trastuzumab-mcc-dm1 et du pertuzumab
WO2015168521A2 (fr) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. Conjugués p97-polynucléotides
KR102062025B1 (ko) 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物
WO2016061231A1 (fr) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition d'interactions de cellules tumorales avec le micro-environnement permettant une réduction de croissance de tumeur et de progression de maladie
EP3302551A2 (fr) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Methodes pour le traitement du cancer du sein her2-positive localement avancé ou métastatique et précédemment non-traité
ES2731377T3 (es) * 2015-07-07 2019-11-15 Hoffmann La Roche Politerapia con un conjugado anticuerpo anti-HER2-fármaco y un inhibidor de bcl-2
WO2017024239A1 (fr) * 2015-08-06 2017-02-09 City Of Hope Conjugués thérapeutiques d'internalisation cellulaire
CA3001712A1 (fr) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Conjugues cibles sstr, et ses particules et formulations
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于***的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于***的抗-her2组合
CN114478801A (zh) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
MX2019003368A (es) 2016-09-23 2019-09-16 Purdue Research Foundation Agentes anticancerigenos y preparacion de los mismos.
US20180140703A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University California Tumor radiosensitization with antibody conjugates
EP3552014A4 (fr) * 2016-12-08 2020-08-12 Washington University Antigène de groupe sanguin incompatible permettant la détection et le traitement du cancer
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
RU2750821C2 (ru) 2017-01-17 2021-07-05 Дженентек, Инк. Препараты антител против her2 для подкожного введения
TW201834697A (zh) * 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
FI3589661T3 (fi) 2017-03-02 2024-01-31 Genentech Inc Her2-positiivisen rintasyövän adjuvanttihoito
AU2018253948A1 (en) * 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
WO2018226802A1 (fr) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction de létalité synthétique à l'aide de la thérapie épigénétique
BR112019027025A2 (pt) 2017-06-23 2020-06-30 Birdie Biopharmaceuticals, Inc. composições farmacêuticas
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
KR20200034369A (ko) 2018-09-21 2020-03-31 건국대학교 글로컬산학협력단 Her2에 특이적으로 결합하는 항체단편 및 이의 용도
WO2020251556A1 (fr) * 2019-06-11 2020-12-17 Io Therapeutics, Inc. Utilisation d'un agoniste de rxr dans le traitement de cancers her2 +
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
MX2022001719A (es) * 2019-08-15 2022-03-11 Silverback Therapeutics Inc Formulaciones de conjugados de benzazepina y usos de las mismas.
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
WO2022020588A1 (fr) * 2020-07-22 2022-01-27 Molecular Templates, Inc. Méthodes cliniques d'utilisation de molécules de liaison à her2
WO2023043883A1 (fr) * 2021-09-15 2023-03-23 Tgv Pharma Inc. Thérapie à trois agents pour le traitement du cancer
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2885396A (en) 1957-03-21 1959-05-05 Heidelberger Charles N-glycosides of 5-fluorouracil
CH605550A5 (fr) 1972-06-08 1978-09-29 Research Corp
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
CA1289880C (fr) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Immunotoxines contre le cancer des ovaires chez les humains et methode d'utilisation
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DE4014540A1 (de) 1990-05-07 1991-11-14 Klaus Dr Tschaikowsky Immunkonjugate zur prophylaxe und therapie von organschaeden bei entzuendlichen prozessen
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
EP0656367A1 (fr) 1991-08-22 1995-06-07 Becton, Dickinson and Company Procédés et compositions de traitements de cancers et de prognostic de réaction aux dits traitements
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
JP3161490B2 (ja) 1993-07-30 2001-04-25 松下電器産業株式会社 金型装置
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CA2227777A1 (fr) 1996-05-23 1997-11-27 Ian Alexander Gilmour Procede d'extraction de proanthocyanidines de substances botaniques
ATE259056T1 (de) 1996-11-06 2004-02-15 Sequenom Inc Verfahren zur massenspektrometrie
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0973804B1 (fr) 1997-04-07 2006-12-27 Genentech, Inc. Anticorps anti-vegf
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
ES2524141T3 (es) 1999-04-01 2014-12-04 Talon Therapeutics, Inc. Composiciones para tratar el cáncer
WO2000064946A2 (fr) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions et procedes de traitement du cancer par inhibition selective de vegf
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
DK2283866T3 (en) 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
EP1189641B1 (fr) * 1999-06-25 2009-07-29 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
JP2003504363A (ja) 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ES2330301T3 (es) 1999-08-27 2009-12-09 Genentech, Inc. Dosificaciones para tratamiento con anticuerpos anti-erbb2.
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
ATE457318T1 (de) 2000-12-28 2010-02-15 Kyowa Hakko Kirin Co Ltd Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1992643A3 (fr) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005063299A2 (fr) 2003-12-24 2005-07-14 Genentech, Inc. Compositions et methodes pour traitement des tumeurs d'origine hematopoietique
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
EP1542723B1 (fr) 2002-08-16 2011-02-23 ImmunoGen, Inc. Agents de reticulation a reactivite et solubilite elevees et utilisation de ceux-ci dans la preparation de conjugues pour l'administration ciblee de medicaments a petites molecules
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20040120949A1 (en) 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
WO2004048525A2 (fr) 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
EP1718667B1 (fr) 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2006096861A2 (fr) 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
EP1959926A1 (fr) 2005-10-25 2008-08-27 Abbott Laboratories Preparation comprenant un medicament faiblement soluble dans l'eau et son procede d'utilisation
AR060631A1 (es) 2006-04-26 2008-07-02 Piramed Ltd Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
KR101422301B1 (ko) * 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 약학적 화합물
US20090098115A1 (en) 2006-10-20 2009-04-16 Lisa Michele Crocker Cell lines and animal models of HER2 expressing tumors
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
MX338504B (es) * 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer

Also Published As

Publication number Publication date
IL207894A0 (en) 2010-12-30
RU2018136076A (ru) 2020-04-13
NZ709293A (en) 2017-01-27
CN104873980A (zh) 2015-09-02
CN102036660B (zh) 2015-05-06
CN102036660A (zh) 2011-04-27
UA127472C2 (uk) 2023-09-06
CN104888231B (zh) 2019-05-17
IL207894A (en) 2015-09-24
CN104873980B (zh) 2019-07-19
CA3146422A1 (fr) 2009-09-24
NZ621433A (en) 2015-10-30
PH12014502133A1 (en) 2015-06-29
PH12014502134B1 (en) 2015-06-29
DK2254571T3 (en) 2015-09-28
IL274393B (en) 2022-09-01
EP2254571B1 (fr) 2015-07-01
CL2009000559A1 (es) 2010-10-15
CR20180483A (es) 2018-12-05
EP3692988A2 (fr) 2020-08-12
KR20190077616A (ko) 2019-07-03
KR20150115951A (ko) 2015-10-14
IL295098A (en) 2022-09-01
ES2629405T3 (es) 2017-08-09
US20170136026A1 (en) 2017-05-18
PL2644204T3 (pl) 2017-09-29
US8663643B2 (en) 2014-03-04
EP3269366A3 (fr) 2018-04-04
AR070865A1 (es) 2010-05-12
NZ602675A (en) 2014-03-28
DK2644204T3 (en) 2017-07-03
IL259499A (en) 2018-07-31
ES2629067T3 (es) 2017-08-07
US20190374547A1 (en) 2019-12-12
PL2644194T3 (pl) 2017-09-29
CA2990929A1 (fr) 2009-09-24
RU2671489C2 (ru) 2018-11-01
JP2018052946A (ja) 2018-04-05
KR102449659B1 (ko) 2022-09-29
EP2638907A2 (fr) 2013-09-18
EP2638907A3 (fr) 2014-05-14
CN104888231A (zh) 2015-09-09
NZ587706A (en) 2012-12-21
TW201611846A (en) 2016-04-01
JP2016040273A (ja) 2016-03-24
MY166446A (en) 2018-06-27
SI2254571T1 (sl) 2015-10-30
JP6016825B2 (ja) 2016-10-26
MY184496A (en) 2021-04-01
HUE035182T2 (hu) 2018-05-02
IL234065A0 (en) 2014-09-30
BRPI0906181A2 (pt) 2015-06-30
US20120107302A1 (en) 2012-05-03
ES2773510T3 (es) 2020-07-13
KR20180035923A (ko) 2018-04-06
PL3269366T3 (pl) 2020-07-27
TWI675668B (zh) 2019-11-01
MX2022000579A (es) 2022-02-10
JP2014132009A (ja) 2014-07-17
WO2009117277A2 (fr) 2009-09-24
TW201511771A (zh) 2015-04-01
RU2510272C2 (ru) 2014-03-27
KR20210131473A (ko) 2021-11-02
CR11678A (es) 2010-12-13
AU2009225877A1 (en) 2009-09-24
EP2644204A2 (fr) 2013-10-02
US20230201210A1 (en) 2023-06-29
RU2018136076A3 (fr) 2021-10-25
KR20230054478A (ko) 2023-04-24
JP5656823B2 (ja) 2015-01-21
SG10201401941RA (en) 2014-07-30
SI2644204T1 (sl) 2017-08-31
PH12014502135B1 (en) 2015-06-29
TWI527593B (zh) 2016-04-01
IL234064A0 (en) 2014-09-30
CA2716592A1 (fr) 2009-09-24
CN104888232A (zh) 2015-09-09
EP3269366B1 (fr) 2020-01-15
IL234064B (en) 2020-05-31
MX2010010168A (es) 2010-10-04
RU2010142390A (ru) 2012-04-27
KR20200113026A (ko) 2020-10-05
CN110251670A (zh) 2019-09-20
WO2009117277A3 (fr) 2010-04-29
HUE025507T2 (en) 2016-02-29
PH12014502135A1 (en) 2015-06-29
HUE035184T2 (en) 2018-05-02
CN110251670B (zh) 2023-11-14
TWI449536B (zh) 2014-08-21
JP2012500180A (ja) 2012-01-05
KR101751065B1 (ko) 2017-06-26
TW200942261A (en) 2009-10-16
IL234065B (en) 2018-06-28
EP3692988A3 (fr) 2020-10-14
ES2545977T3 (es) 2015-09-17
AU2009225877B2 (en) 2014-11-20
EP3269366A2 (fr) 2018-01-17
SI2644194T1 (sl) 2017-08-31
US20140140993A1 (en) 2014-05-22
MY188477A (en) 2021-12-13
CN104888232B (zh) 2019-05-10
KR20100129318A (ko) 2010-12-08
EP2644194A3 (fr) 2014-01-01
EP2644204B1 (fr) 2017-04-19
KR20160125535A (ko) 2016-10-31
MX353429B (es) 2018-01-12
DK2644194T3 (en) 2017-07-03
SG10201401942PA (en) 2014-08-28
PH12019501792A1 (en) 2021-03-22
IL274393A (en) 2020-06-30
RU2013147514A (ru) 2015-04-27
JP2020147570A (ja) 2020-09-17
PH12014502134A1 (en) 2015-06-29
EP2254571A2 (fr) 2010-12-01
PH12014502133B1 (en) 2015-06-29
CA2990929C (fr) 2022-04-12
SG10202104314YA (en) 2021-06-29
IL234066A0 (en) 2014-09-30
TW201722475A (zh) 2017-07-01
EP2644194B1 (fr) 2017-04-19
KR101772304B1 (ko) 2017-08-28
JP6705788B2 (ja) 2020-06-03
CA2716592C (fr) 2018-02-27
JP6388859B2 (ja) 2018-09-12
HK1147444A1 (en) 2011-08-12
PL2254571T3 (pl) 2015-11-30
EP2644204A3 (fr) 2014-02-12
TWI574698B (zh) 2017-03-21
MY166445A (en) 2018-06-27
ZA201006186B (en) 2011-11-30
EP2644194A2 (fr) 2013-10-02
UA108832C2 (uk) 2015-06-25

Similar Documents

Publication Publication Date Title
MA32223B1 (fr) Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation
Boehrer et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Dubovsky et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
Zhai et al. Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells
Abate et al. Elements in support of the ‘non-identity’of the PGRMC1 protein with the σ2 receptor
MX2021004410A (es) Inhibidores de la proteina tirosina fosfatasa.
MX2021012122A (es) Inhibidores de la proteina tirosina fosfatasa.
MA33614B1 (fr) Composés de benzoxépine inhibiteurs de pi3k et leurs procédés d'utilisation
MA31339B1 (fr) Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
Larghero et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
JP7044059B2 (ja) 抗がん剤の評価方法
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
US20190029984A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
Zdżalik-Bielecka et al. Bemcentinib and gilteritinib inhibit cell growth and impair the endo-lysosomal and autophagy systems in an AXL-independent manner
Zhitomirsky et al. The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes
Advani et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
Ćojbašić et al. Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up
Castelletti et al. The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors
Kim et al. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells
Lee et al. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
Dekeister et al. Sunitinib-induced sudden hearing loss
Türkoglu et al. Indomethacin-induced psychotic disorder
Ansari et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models